Application 021611
- Type
- NDA
- Sponsor
- ENDO PHARMS
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | OPANA | OXYMORPHONE HYDROCHLORIDE | TABLET;ORAL | 5MG | Yes | No |
| 002 | OPANA | OXYMORPHONE HYDROCHLORIDE | TABLET;ORAL | 10MG | Yes | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021611-001 | OPANA | OXYMORPHONE HYDROCHLORIDE | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | |
| N021611-002 | OPANA | OXYMORPHONE HYDROCHLORIDE | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021611-001 | OPANA | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021611-002 | OPANA | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2006-06-22 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021611-001 | OPANA | 5MG | TABLET / ORAL | RLD | 2006-06-22 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021611-002 | OPANA | 10MG | TABLET / ORAL | RLD | 2006-06-22 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021611-001 | OPANA | 5MG | TABLET / ORAL | RLD | 2006-06-22 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021611-002 | OPANA | 10MG | TABLET / ORAL | RLD | 2006-06-22 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021611-001 | OPANA | 5MG | TABLET / ORAL | RLD | 2006-06-22 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021611-002 | OPANA | 10MG | TABLET / ORAL | RLD | 2006-06-22 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021611-001 | OPANA | 5MG | TABLET / ORAL | AB | RLD | 2006-06-22 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N021611-002 | OPANA | 10MG | TABLET / ORAL | AB | RLD, RS | 2006-06-22 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N021611-001 | OPANA | 5MG | TABLET / ORAL | RLD | 2006-06-22 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | N021611-002 | OPANA | 10MG | TABLET / ORAL | RLD | 2006-06-22 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N021611-001 | OPANA | 5MG | TABLET / ORAL | RLD | 2006-06-22 | 782e0a99824c… | |
| 2021-12-28 21:50 UTC | 2021-12 | N021611-002 | OPANA | 10MG | TABLET / ORAL | RLD | 2006-06-22 | 782e0a99824c… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N021611-001 | AB | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N021611-002 | AB | 1 | 74a2ff9319b5… |
| 2019-12-14 00:12 UTC | 2019-12 | N021611-001 | AB | 1 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N021611-002 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N021611-001 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N021611-002 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N021611-001 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N021611-002 | AB | 1 | ea99ee380514… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021611-001 | M-14 | 2022-10-25 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021611-002 | M-14 | 2022-10-25 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N021611-001 | M-14 | 2022-10-25 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | N021611-002 | M-14 | 2022-10-25 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N021611-001 | M-14 | 2022-10-25 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | N021611-002 | M-14 | 2022-10-25 | 4b0b4de00fa7… |
| 2022-03-09 01:35 UTC | 2022-03 | N021611-001 | M-14 | 2022-10-25 | bb7c543d1eb4… |
| 2022-03-09 01:35 UTC | 2022-03 | N021611-002 | M-14 | 2022-10-25 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N021611-001 | M-14 | 2022-10-25 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | N021611-002 | M-14 | 2022-10-25 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021611-001 | M-14 | 2022-10-25 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021611-002 | M-14 | 2022-10-25 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N021611-001 | M-14 | 2022-10-25 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | N021611-002 | M-14 | 2022-10-25 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N021611-001 | M-14 | 2022-10-25 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | N021611-002 | M-14 | 2022-10-25 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N021611-001 | M-14 | 2022-10-25 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | N021611-002 | M-14 | 2022-10-25 | c0c555d07b60… |
| 2023-01-26 05:58 UTC | 2023-01 | N021611-001 | M-14 | 2022-10-25 | 3bdfa0b2c4d7… |
| 2023-01-26 05:58 UTC | 2023-01 | N021611-002 | M-14 | 2022-10-25 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021611-001 | M-14 | 2022-10-25 | 3a93d1ddd44b… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021611-002 | M-14 | 2022-10-25 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | N021611-001 | M-14 | 2022-10-25 | f41ea6bd6efb… |
| 2022-10-28 04:53 UTC | 2022-10 | N021611-002 | M-14 | 2022-10-25 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | N021611-001 | M-14 | 2022-10-25 | e64feba35796… |
| 2022-09-29 23:25 UTC | 2022-09 | N021611-002 | M-14 | 2022-10-25 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N021611-001 | M-14 | 2022-10-25 | cb3db0bc1861… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N021611-002 | M-14 | 2022-10-25 | cb3db0bc1861… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Oxymorphone Hydrochloride | OXYMORPHONE HYDROCHLORIDE | Aurolife Pharma, LLC | 22c7652a-aa16-4fa8-89d9-517e69059068 | 2026-06-29 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
| Oxymorphone Hydrochloride | OXYMORPHONE HYDROCHLORIDE | KVK-Tech, Inc. | dcb5b5d2-7d0a-497a-8f1e-3b96fd43320b | 2026-01-30 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
| Oxymorphone hydrochloride | OXYMORPHONE HYDROCHLORIDE | Amneal Pharmaceuticals LLC | 3f4e703a-e398-42fd-8759-e398c79955f1 | 2026-01-15 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
| Oxymorphone Hydrochloride | OXYMORPHONE HYDROCHLORIDE | Epic Pharma, LLC | 95804e72-232d-425d-b23d-a66f43bdf0c6 | 2025-12-15 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
| Oxymorphone Hydrochloride | OXYMORPHONE HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 3eb971cf-ab82-49f3-a46c-4d76a8ce599e | 2025-12-12 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
| OXYMORPHONE HYDROCHLORIDE | OXYMORPHONE HYDROCHLORIDE | Camber Pharmaceuticals, Inc | 06af7dff-c261-4c03-9cd9-0605c42507fa | 2025-08-18 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
| Oxymorphone hydrochloride | OXYMORPHONE HYDROCHLORIDE | Amneal Pharmaceuticals of New York LLC | 557e9610-62d7-42bf-90c1-44215bd8c1f8 | 2024-01-10 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
| OXYMORPHONE HYDROCHLORIDE | OXYMORPHONE HYDROCHLORIDE | Bryant Ranch Prepack | 560e9425-dfcb-4fb4-a759-b1e3f8f40fdb | 2024-01-09 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
| OXYMORPHONE HYDROCHLORIDE | OXYMORPHONE HYDROCHLORIDE | XLCare Pharmaceuticals, Inc. | 1a1d5061-b62a-49fa-a5b2-4970f51416ae | 2020-05-07 | Boxed warning, Warnings, Adverse reactions | OXYMORPHONE HYDROCHLORIDE |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 60951-794 | Oxymorphone Hydrochloride | Oxymorphone Hydrochloride | Par Pharmaceutical | NDA AUTHORIZED GENERIC | Current |
| 60951-794 | Oxymorphone Hydrochloride | Oxymorphone Hydrochloride | Par Pharmaceutical | NDA AUTHORIZED GENERIC | Current |
| 60951-795 | Oxymorphone Hydrochloride | Oxymorphone Hydrochloride | Par Pharmaceutical | NDA AUTHORIZED GENERIC | Current |
| 60951-795 | Oxymorphone Hydrochloride | Oxymorphone Hydrochloride | Par Pharmaceutical | NDA AUTHORIZED GENERIC | Current |
| 63481-612 | OPANA | Oxymorphone Hydrochloride | Endo Pharmaceuticals, Inc. | NDA | Current |
| 63481-612 | OPANA | Oxymorphone Hydrochloride | Endo Pharmaceuticals Inc. | NDA | Current |
| 63481-612 | OPANA | Oxymorphone Hydrochloride | Endo Pharmaceuticals Inc. | NDA | Current |
| 63481-612 | OPANA | Oxymorphone Hydrochloride | Endo Pharmaceuticals, Inc. | NDA | Current |
| 63481-613 | OPANA | Oxymorphone Hydrochloride | Endo Pharmaceuticals, Inc. | NDA | Current |
| 63481-613 | OPANA | Oxymorphone Hydrochloride | Endo Pharmaceuticals Inc. | NDA | Current |
| 63481-613 | OPANA | Oxymorphone Hydrochloride | Endo Pharmaceuticals Inc. | NDA | Current |
| 63481-613 | OPANA | Oxymorphone Hydrochloride | Endo Pharmaceuticals, Inc. | NDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 76234 | ORIG | 2023-11-03 |
| 60693 | SUPPL | 2019-10-29 |
| 60685 | SUPPL | 2019-10-28 |
| 60684 | SUPPL | 2019-10-28 |
| 60361 | SUPPL | 2019-10-08 |
| 60358 | SUPPL | 2019-10-08 |
| 55991 | SUPPL | 2018-10-17 |
| 55990 | SUPPL | 2018-10-17 |
| 55683 | SUPPL | 2018-10-01 |
| 55682 | SUPPL | 2018-10-01 |
| 46353 | SUPPL | 2016-12-21 |
| 46287 | SUPPL | 2016-12-20 |
| 15873 | SUPPL | 2014-05-14 |
| 5852 | SUPPL | 2012-07-11 |
| 5851 | SUPPL | 2011-02-10 |
| 37337 | SUPPL | 2011-02-09 |
| 5850 | SUPPL | 2010-04-22 |
| 42232 | ORIG | 2008-10-03 |
| 28244 | SUPPL | 2006-08-07 |
| 37336 | SUPPL | 2006-08-04 |
| 15872 | ORIG | 2006-06-28 |
| 5849 | ORIG | 2006-06-28 |
| 63214 | SUPPL | 1900-01-01 |
| 63213 | SUPPL | 1900-01-01 |